Physician profile
Ryan H Devine
NPI 1568622207
$11,834.33
in general payments reported to CMS, 2019-2025
69 companies · $1,168 in 2025
The $1,168 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,637 · 2020: $3,328 · 2021: $2,317 · 2022: $2,753 · 2023: $69.17 · 2024: $562 · 2025: $1,168.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,633 · Consulting Fee: $150 · Education: $15.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,632.69 |
| Consulting Fee | $150.00 |
| Education | $15.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $1,452.18 | 2019-2025 | Tagrisso, Enhertu |
| Pfizer INC. | $900.79 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $806.20 | 2019-2024 | Krazati, Augtyro |
| Merck Sharp & Dohme LLC | $618.07 | 2019-2025 | Keytruda, Lynparza |
| Janssen Biotech, INC. | $436.83 | 2019-2025 | Darzalex, Tecvayli, Talvey |
| Seagen INC. | $424.90 | 2019-2022 | |
| Amgen INC. | $415.99 | 2019-2023 | Blincyto, Kyprolis |
| Lilly USA, LLC | $415.97 | 2019-2022 | |
| Daiichi Sankyo INC. | $403.94 | 2019-2025 | Datroway |
| Astellas Pharma US INC | $357.50 | 2020-2022 | |
| Sirtex Medical INC | $322.04 | 2020-2022 | |
| Glaxosmithkline, LLC. | $317.76 | 2019-2025 | Ojjaara, Zejula, Jemperli |
| Celgene Corporation | $279.38 | 2019-2025 | Reblozyl, Opdualag |
| Genzyme Corporation | $273.07 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $248.28 | 2019-2022 |
Show all 69 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ryan Devine listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.